Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents

Pediatric Nephrology

Volumn 23, Issue 12, 2008, Pages 2121-2129

  Penfield, Jeffrey G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Contrast agents; End stage renal disease; Gadolinium; Kidney disease; Magnetic resonance imaging; Nephrogenic systemic fibrosis

Indexed keywords

CIDOFOVIR; CORTICOSTEROID; ERYTHROPOIETIN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IODINATED CONTRAST MEDIUM; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; SODIUM THIOSULFATE; STEROID;

CELLULITIS; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; GLOMERULUS FILTRATION RATE; HALF LIFE TIME; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERITONEAL DIALYSIS; PHOTOTHERAPY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCLERODERMA; SCLEROMYXEDEMA; SINGLE DRUG DOSE; SKIN BIOPSY;

ADOLESCENT; CHILD; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; NEPHROGENIC FIBROSING DERMOPATHY; RISK FACTORS; STEROIDS; YOUNG ADULT;

EID: 55649120234     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-0862-6     Document Type: Review

References (77)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000-1001
2. Daram SR, Cortese CM, Bastani B (2005) Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis 46:754-759
3. Auron A, Shao L, Warady BA (2006) Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 21:1307-1311
4. Jain SM, Wesson S, Hassanein A, Canova E, Hoy M, Fennell RS, Dharnidharka VR (2004) Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19:467-470
5. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ (2003) Nephrogenic fibrosing dermopathy: Two pediatric cases. J Pediatr 143:678-681
6. Cowper SE (2003) Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 15:785-790
7. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238-249
8. Streams BN, Liu V, Liegeois N, Moschella SM (2003) Clinical and pathologic features of nephrogenic fibrosing dermopathy: A report of two cases. J Am Acad Dermatol 48:42-47
9. Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol 25:358
10. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, Haddad R, Shanahan JC (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50:2660-2666
11. Parsons AC, Yosipovitch G, Sheehan DJ, Sangüeza OP, Greenberg CS, Sane DC (2007) Transglutaminases: The missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 29:433-436
12. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383-393
13. Levine JM, Taylor RA, Elman LB, Bird SJ, Lavi E, Stolzenberg ED, McGarvey ML, Asbury AK, Jimenez SA (2004) Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 30:569-577
14. Keyrouz S, Rudnicki SA (2007) Neuromuscular involvement in nephrogenic systemic fibrosis. J Clin Neuromuscul Dis 9:297-302
15. Krous H, Breisch E, Chadwick A, Pinckney L, Malicki DM, Benador N (2007) Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing sarcoma, end stage renal disease, and hemodialysis. Pediatr Dev Pathol 10:395-402
16. Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X (2006) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 54:S31-34
17. Centers for Disease Control and Prevention (CDC) (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents' St Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56:137-141
18. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort. Radiology 245:168-175
19. Richmond H, Zwerner J, Kim Y, Fiorentino D (2007) Nephrogenic systemic fibrosis: Relationship to gadolinium and response to photopheresis. Arch Dermatol 143:1025-1030
20. Todd DJ, Kagan A, Chibnik LB, Kay J (2007) Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56:3433-3441
21. Wahba IM, Simpson EL, White K (2007) Gadolinium is not the only trigger for nephrogenic systemic fibrosis: Insights from two cases and review of the recent literature. Am J Transplant 7:2425-2432
22. Weiss AS, Lucia MS, Teitelbaum I (2007) A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 3:111-115
23. Kucher C, Xu X, Pasha T, Elenitsas R (2005) Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 32:484-490
24. Gelpi E, de la Paz MP, Terracini B, Abaitua I, de la Cámara AG, Kilbourne EM, Lahoz C, Nemery B, Philen RM, Soldevilla L, Tarkowski S, WHO/CISAT Scientific Committee for the Toxic Oil Syndrome. Centro de Investigación para el Síndrome del Aceite Tóxico (2002) The Spanish toxic oil syndrome 20 years after its onset: A multidisciplinary review of scientific knowledge. Environ Health Perspect 110:457-464
25. Silver RM, Heyes MP, Maize JC, Quearry B, Vionnet-Fuasset M, Sternberg EM (1990) Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 322:874-881
26. Grobner T (2006) Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104-1108
27. Danish Medicines Agency (online 29 May 2006) Investigation of the safety of MRI contrast medium Omniscan [press release] [http://www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID=8931]
28. Penfield JG, Reilly RF Jr (2007) What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3:654-668
29. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol 188:586-592
30. Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264-267
31. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN (2007) Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22:3179-3185
32. Reilly RF (2008) Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3:747-751
33. Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39:138-142
34. High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21-26
35. Thakral C, Abraham JL (2007) Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. J Electron Microsc 56:181-187
36. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2007) Dermal inorganic gadolinium concentrations: Evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158:273-280
37. High WA, Ayers RA, Cowper SE (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:710-712
38. Saussereau E, Lacroix C, Cattaneo A, Mahieu L, Goulle JP (2008) Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci 176:54-57
39. Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: Is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:73-76
40. Thomsen HS, Marckmann P, Logager VB (2007) Nephrogenic systemic fibrosis (NSF): A late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7:130-137
41. Wedeking P, Kumar K, Tweedle MF (1992) Dissociation of gadolinium chelates in mice: Relationship to chemical characteristics. Magn Reson Imaging 10:641-648
42. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: A review. Fundam Clin Pharmacol 20:563-576
43. Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491-502
44. European Medicines Agency: EPARs for Authorised Medicinal Products for Human Use. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/ optimark/optimark.htm, accessed 29 November 2007
45. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A (2007) Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243:148-157
46. Saab G, Abu-Alfa A (2007) Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? Radiology 244:930-931; author reply 931-932
47. US Food and Drug Administration: Information on Gadolinium-Containing Contrast Agents. Available at http://www.fda.gov/cder/drug/infopage/gcca/ default.htm
48. Grobner T, Prischl FC (2007) Gadolinium and nephrogenic systemic fibrosis. Kidney Int 72:260-264
49. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362
50. Hubbard V, Davenport A, Jarmulowicz M, Rustin M (2003) Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 148:563-568
51. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48:55-60
52. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD (2003) Nephrogenic fibrosing dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563-572
53. Goveia M, Chan BP, Patel PR (2007) Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 57:725-727
54. Perazella MA, Ishibe S, Perazella MA, Reilly RF (2003) Nephrogenic fibrosing dermopathy: An unusual skin condition associated with kidney disease. Semin Dial 16:276-280
55. Pieringer H, Schmekal B, Janko O, Biesenbach G (2007) Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 22:3094
56. Gilliet M, Cozzio A, Burg G, Nestle FO (2005) Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152:531-536
57. Kintossou R, D'Incan M, Chauveau D, Bens G, Franck F, Dauplat MM, Viraben R, Déchelotte P, Souteyrand P (2007) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis: Role of gadolinium? Ann Dermatol Venereol 134:667-671
58. Lauchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W (2004) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208:278-280
59. Steen H, Schwenger V (2007) Good MRI images: To Gad or not to Gad? Pediatr Nephrol 22:1239-1242
60. Thomsen HS, Almen T, Morcos SK (2002) Gadolinium-containing contrast media for radiographic examinations: A position paper. Eur Radiol 12:2600-2605
61. Morcos SK, Thomsen HS, Webb JA (1999) Contrast-media-induced nephrotoxicity: A consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 9:1602-1613
62. Blondin D, Koester A, Andersen K, Kurz KD, Moedder U, Cohnen M (2007) Renal transplant failure due to urologic complications: Comparison of static fluid with contrast-enhanced magnetic resonance urography. Eur J Radiol DOI 10.1016/j.ejrad.2007.10.026
63. Staatz G, Nolte-Ernsting CC, Haage P, Tacke J, Rohrmann D, Stollbrink C, Günther RW (2001) Gadolinium-enhanced T(1)-weighted MR urography versus T(2)-weighted (HASTE) MR urography in children. Rofo 173:991-996
64. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y (2006) Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24:445-451
65. Broome DR, Cottrell AC, Kanal E (2007) Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?". AJR Am J Roentgenol 189:W234-W235
66. Pharmacovigilance Working Party (PhVWP) of the Committee for Medicinal Products for Human Use (CHMP). Available at http://www.mhra.gov.uk/home/ groups/pl-p/documents/websiteresources/con2030232.pdf
67. Dharnidharka VR, Wesson SK, Fennell RS (2006) Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 22:1395
68. DiCarlo JB, Gupta EA, Solomon AR (2007) A pediatric case of nephrogenic fibrosing dermopathy: Improvement after combination therapy. J Am Acad Dermatol 54:914-916
69. Sanchez-Ross M, Snyder R, Colome-Grimmer MI, Blumberg M, Huttenbach Y, Raimer S (2007) Nephrogenic fibrosing dermopathy in a patient with systemic lupus erythematosus and acute lupus nephritis. Pediatr Dermatol 24:E36-39
70. Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: An autopsy case and review of the literature. Arch Pathol Lab Med 130:209-212
71. Ting WW, Stone MS, Madison KC, Kurtz K (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139:903-906
72. Morcos SK (2007) Erratum of Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: Is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80:586
73. Kafi R, Fisher GJ, Quan T, Shao Y, Wang R, Voorhees JJ, Kang S (2004) UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140:1322-1324
74. Wahba IM, White K, Meyer M, Simpson EL (2007) The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy-report of two cases and review of the literature. Nephrol Dial Transplant 22:631-636
75. Baron PW, Cantos K, Hillebrand DJ, Hu KQ, Ojogho ON, Nehlsen-Cannarella S, Concepcion W (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25:204-209
76. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R (2007) Nephrogenic systemic fibrosis: A mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2:258-263
77. Chung HJ, Chung KY (2004) Nephrogenic fibrosing dermopathy: Response to high-dose intravenous immunoglobulin. Br J Dermatol 150:596-597